Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Nova Mentis Life Science Corp. C.LIB

Healthcare Drug Manufacturers - Major Cannabis
Nova Mentis Life Science Corp is a Canadian-based company focused on building and supporting a diversified portfolio of health and wellness businesses. Through its subsidiary, the company is focused on exploring the anti-inflammatory effects of psilocybin in underexplored metabolic indications such as obesity and diabetes and providing a Health Canada Standard Licensed facility focused on the cultivation of AAAA premium, small batch, terpene rich dominant cultivars cured to perfection.


CSE:LIB - Post by User

Nova Mentis Life Science Corp. > Financial Post Article
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(2)
•••
Comment by rcash1on Jan 22, 2018 11:07pm
221 Views
Post# 27413155

RE:RE:RE:RE:RE:RE:RE:Financial Post Article

RE:RE:RE:RE:RE:RE:RE:Financial Post ArticleAll good just a few thoughts in there . That's a guessing game , if it's first or last just as it's licensed. I might have put another acquisitions in there as well first , but that's just speculation . I'd have to reshuffle the order then too  . Lol  There really is a lot of short term objectives that will produce revenue and that's good for shareholders.  
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities